Prognostic variables that may influence treatment decisions for cardiac sarcoidosis
| • Age >50 years |
| • Left ventricular ejection fraction <40% |
| • New York Heart Association Functional Class III or IV |
| • Increased left ventricular end-diastolic diameter |
| • Late gadolinium enhancement on cardiac magnetic resonance imaging |
| • Ventricular tachycardia |
| • Cardiac inflammation identified by fluorodeoxyglucose positron emission tomography scan |
| • Echocardiographic evidence of abnormal global longitudinal strain |
| • Interventricular septal thinning |
| • Elevated troponin or brain natriuretic peptide |
Features found to be associated with increased risk for morbidity or mortality from cardiac sarcoidosis [150–159].